About this source
- Kind
- Research
- Design
- RCT, Human clinical trial
- Population
- Human, Stage 2 or 3 neurotrophic keratopathy; 18 subjects in the healing comparison (10 RGN-259, 8 placebo)
- Sample size
- 18
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
Very small trial. The complete-healing comparison at 4 weeks (6 of 10 versus 1 of 8) gave p = 0.0656, above the usual 0.05 threshold. Eye drops of full-length thymosin beta-4, not the TB-500 fragment. Verified from the Europe PMC abstract record.
Cited in
Neurotrophic keratopathy Phase III
Thymosin beta-4 · Research finding
Limited
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.